Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors inside the central anxious system, conolidine modulates alternate molecular targets. A Science Advancements study identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabi... https://heinzc945bki6.wikisona.com/user